tbuckley/cabot-search huggingface dataset:
The intraepithelial lesion: a spectrum of problems
Authors: D. K. Ohrt
Journal: JAMA (1989)

The Bethesda System described in this week's issue ofThe Journalis an improved approach to reporting cervical/vaginal cellular abnormalities.<sup>1</sup>When abnormal, the "routine Pap smear" initiates a complex chain of events, judgments, and interactions. From a quality assurance perspective, it is necessary that each link be carefully performed if the clinical episode as a whole is to have any utility. The attending physician, cytopathologist, and the patient herself all have roles that will make or break this concatenation.<sup>2</sup> Backed by their office managers, attending physicians have too often sought the low-price competitor with the best turnaround time. Ironically, as the price of reading and interpreting cervical cytology samples has been leveraged downward by competition for contracts, the price to the patient or payer has been pushed upward. Some physicians have become much like brokers, all too often failing to concern themselves with the necessary balance of cost
Influence of Cobalt and Sheep Erythropoietin on Radioactive Iron Incorporation in RBC of Starved Intact and Nephrectomized Rats
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Birth defects related to bendectin use in pregnancy. I. Oral clefts and cardiac defects
Authors: A. A. Mitchell
Journal: JAMA (1981)

The risks of birth defects previously associated with Bendectin use in early pregnancy were evaluated in a case-control study of malformed infants whose mothers were interviewed in three regional centers; 98 infants with isolated cleft palate (CP), 221 with cleft lip with or without cleft palate (CL±CP), and 122 with selected heart defects (HD) were compared with 970 other malformed infants who served as controls. Relative risk estimates (with their 95% confidence limits) for first-trimester exposure to Bendectin were as follows; CP, 0.9 (0.5 to 1.5); CL±CP, 0.6 (0.4 to 0.8); and HD, 1.0 (0.6 to 1.6). Allowance for a large number of potentially confounding factors did not materially influence the risk estimates. These findings suggest that early in utero exposure to Bendectin does not appreciably increase the risk of oral clefts or selected cardiac defects. (<i>JAMA</i>1981;245:2311-2314)
Fetal Extracts and Leukocyte Migration Inhibition: Reply
Authors: Zöller M., Matzku S.
Journal: JNCI Journal of the National Cancer Institute (1980)

Fetal Extracts and Leukocyte Migration Inhibition: Reply Get access Zöller M., Zöller M. Institute of Nuclear Medicine, German Cancer Research CenterD-6900 Heidelberg, Federal Republic of Germany Search for other works by this author on: Oxford Academic PubMed Google Scholar Matzku S. Matzku S. Institute of Nuclear Medicine, German Cancer Research CenterD-6900 Heidelberg, Federal Republic of Germany Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 65, Issue 1, July 1980, Page 5, https://doi.org/10.1093/jnci/65.1.5-a Published: 01 July 1980
3D Printing Nanoscale Bioactive Glass Scaffolds Enhance Osteoblast Migration and Extramembranous Osteogenesis through Stimulating Immunomodulation
Authors: Fujian Zhao, Weihan Xie, Wen Zhang, Xiaoling Fu, Wendong Gao, Bo Lei, Xiaofeng Chen*
Journal: Advanced Healthcare Materials (2021)

Adv. Healthcare Mater. 2018, 7, 1800361 https://doi.org/10.1002/adhm.201800361 In the original version of this article, in Figure 3A, the image of the BGSE+RAW group after 7 days was incorrect. The corrected figure is shown below. This mistake doesn't affect any conclusions made in the paper. The authors apologize for any inconvenience caused to the readers by this change.
Exstrophy of Bladder: Review of 50 Cases Treated by Functional Closure
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Brain Serotonin Neurotoxicity and Fenfluramine and Dexfenfluramine
Authors: Richard B. Rothman
Journal: JAMA (1997)

<h3>To the Editor.</h3> —Dr McCannnd colleagues<sup>1</sup>state "subsequently, several centers reported cases of PPH [primary pulmonary hypertension] in users of anorexigens, both amphet-aminelike drugs and serotonin uptake inhibitor agents." A similar statement implicating "amphetamine-type" agents in PPH also appeared in an earlier review by one of the authors.<sup>2</sup>Unless rigorous data support such statements, it is incorrect to link entire classes of medication, whether grouped according to their approved indication or according to their mechanism of action, to a particular adverse effect. For example, there is no evidence linking selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine or sertraline to PPH. Indeed, the authors are probably referring to fenfluramine, which, unlike the SSRIs, is a substrate of the 5-hydroxytryptamine (5-HT) transporter and therefore releases 5-HT. Similarly, the term<i>amphetaminelike</i>is ill defined. Does this refer to the chemical structure, to a stimulant effect in animal behavioral assays, or to an
Association News
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
INSTRUCTION IN LEGAL MEDICINE
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Commentaire de travail de A. Moss et al., pp. 400
Journal: Endoscopy (2010)

See also: Lesion isolation by circumferential submucosal incision prior to endoscopic mucosal resection (CSI-EMR) substantially improves en bloc resection rates for 40-mm colonic lesionsEndoscopy 2010; 42(05): 400-404DOI: 10.1055/s-0029-1243990
'Do not resuscitate' orders. Incidence and implications in a medical-intensive care unit
Authors: S. J. Youngner
Journal: JAMA (1985)

"Do not resuscitate" (DNR) decisions were examined in a medical intensive care unit (MICU) of a 1,000-bed hospital. Seventy-one (14%) of 506 study patients were designated DNR; nine survived hospitalization. Severity of illness, age, and prior health were predictive of DNR orders; race and socioeconomic factors were not. The DNR patients consumed more resources, both before and after DNR orders. Interventions started before DNR designation were continued in at least 76% of patients. Documented justifications of DNR decisions included poor prognosis (59%), poor quality of life (24%), and patients' wishes (15%). There were no written justifications for the DNR decisions in 30 cases (42%). Although willingness to write DNR orders in an MICU and continued active treatment of DNR patients are both reassuring in a general sense, they raise questions about the consistency of treatment plans and goals for individual patients. (<i>JAMA</i>1985;253:54-57)
Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial.
Journal: Journal of Clinical Oncology (1989)

A total of 249 patients with advanced, symptomatic colorectal cancer who received no previous cytostatic therapy were randomly allocated to receive either fluorouracil (5-FU), 600 mg/m2, for 2 days or the following regimen: sequential methotrexate, 250 mg/m2, during the first 2 hours and 5-FU, 500 mg/m2, at hours 3 and 23 followed by leucovorin rescue initiated at hour 24 (15 mg x 8) (MFL). Treatment was repeated every 14 days for eight courses and then continued every 3 to 4 weeks. Five patients were unevaluable. In these groups the objective response could be evaluated in 69% and 73%, respectively, of the patients who received at least four treatment courses, whereas other outcomes were assessed in all randomized patients. The sequential MFL treatment was more effective than 5-FU alone, as indicated by the former's clinically and statistically highly significant advantage regarding the objective (complete [CR] plus partial [PR]) response rates (24% v 3%; P less than .001), subjective response rate (45% v 23%; P less than .001), and survival (median, 8.5 v 6 months; P less than .02). If all patients were considered for objective response, the figures were lower, 17% v 2%, but the difference was still statistically significant (P less than .001). All responses had a minimum duration of 4 months. Overall, the toxicity was low and comparable between the groups, but stomatitis and conjunctivitis were more common after sequential treatment. Our data suggest that the experimentally observed synergistic cell kill between methotrexate and 5-FU has clinical relevance and that the sequential MFL regimen is a superior alternative to 5-FU alone in the treatment of patients with advanced symptomatic colorectal cancer.
Evolving strategies for the management of atrial fibrillation. The role of amiodarone
Authors: N. A. Estes
Journal: JAMA (1992)

Management strategies for the most common sustained cardiac arrhythmia,<sup>1,2</sup>atrial fibrillation, have undergone considerable evolution over the last several years. The objectives of therapy are to slow ventricular rate and restore and maintain sinus rhythm. Prevention of symptoms and reduction in the risk of complications such as stroke are therapeutic goals with agents that slow atrioventricular nodal conduction, antiarrhythmic agents, and anticoagulants. The utility of digoxin for rate control has been questioned with recent studies suggesting that this former mainstay of therapy may now play a subsidiary role.<sup>3</sup>β-Blockers and calcium channel blockers are now frequently used for slowing ventricular response. Concerns regarding the safety of quinidine have been raised by a recent meta-analysis showing an increased mortality in patients randomized to quinidine therapy or placebo for atrial fibrillation,<sup>4</sup>although there are many limitations to this retrospective analysis. These safety concerns have been extended with recent observations
Error in Table.
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
JAMA Pediatrics
Authors: Phil Fontanarosa, Annette Flanagin, Brenda Gregoline, Tracy Frey, Shannon Sparenga, Miriam Cintron, Paul Ruich, Suzanne Walker, Diane Cannon, Connie Manno, Fred Marshall, Catherine Copyreaders, Stephanie Alden, Jan Beckmeyer, Mary Clavey, Paula Coerver-Connolly, Laura Glitman, Kenneth King, Donna Lane, Caroline Thordsen, Wanda Assistant, Larry Bryant, Monica Mungle, Elaine Williams, Kathryn Brokke, Fanny Brown, Paul Frank, Lenette Gardner-Gullens, Peter Kim, Rachell Lozano, Michaela Mark, Elizabeth Scientifi, Michael Berkwits, Michelle Kurzynski, Eric Butkus, Will English, Mustafa Ishaq, Daniel Morrow, Reuben Rios, Ronna Henry, Joshua Bird, Karen Bucher, Samantha Welker, David Song, Deputy Livingston, Thomas Cole, Marla Hall, Deanna Willis, Yolanda Davis, Joseph Thornton, Preeti Malani, Deanna Bellandi, Jim Periodical, Thomas Easley Vice, Brian Shields, Monica Smith, Jeff Ery, J Bonistalli Manager, Kathy Russell, Mirna Monal, Tim Melroy, Marketing Thornbury, Tricia Classifi, Thalia Moss, Mike Harvey, Susan Henning, Saskia Bolore, Gretchen Linder, Brian Mccartney, David Baum, Rebecca Haas, Christine Hearne, Natasha Nekola, Ron Thomas, Paul Gee, Matt Herron, Elizabeth Solaro, Geoff Rey, Rick Bell, Lindsay Dawson, Craig Mccaff Rey, Michael Mcgraw, Romando Rossini, Stacy Staff, Millette Jackson-Bates, Karen Adams-Taylor, Karl Elvin, Jaye Mize, Sean O'donnell, Sue Managers, David Antos, Chris Borden, Debbie Camp, Lydia Cruz, Scott Curl, Diane Darnell, Colleen Kelly, Chris Meyer, Annemarie Neff, J Neff, Sean Ohlson, Phil O'leary, Bill Pedone, Susan Price, Denise Steinhauser, Joe Advertising, Production Services, Kim Boler, Rhonda Brown, Timothy Burke, Daniel Degroot, Jordynn Farrar, Euwanaha Joiner-Smith, Cindy Rendlen, Ellen Yoshihara, Circulation Services, Julie Burton, Dexter Golden, Erin Hinchcliff, Noemi Rivera, Geneine Van, Someren Composition, New Media, Gail Barrett, Regina Brownlee, Amanda Camino, Brenda Chandler-Grayer, Emily Dunn, Amy Evers, Teri Hutchison, Mary Kuranda, Joshua Lampinen, Nathan Mitre, Patricia Panek, La Son, Diggs Sledge, George Thomson Graphics, Joe Amft, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Daniel James, Judith Literskis, Teresa Omiotek, James Madara, Bernard Hengesbaugh, Dimitri Christakis, Washington Joff, Ron Keren, Debra Palazzi, Suzanne Shuey, Samir Shah, Howard Bauchner, Frederick Rivara, Joyce Lee, Ann Arbor, Jay Berry, Cherrie Boyer, San Francisco, Maria Britto, John Campo, Aaron Carroll, Indiana Frank, Joseph Chaloupka, Mitchell Cohen, Sandra Friedman, Kathleen Colorado, Iowa Janz, Terry City, Joyce Klassen, Ann Lee, Michigan Arbor, Huckaby Michelle, Aaron Lewis, Shawn Milstone, Samir Rangel, Martha Shah, Jean-Claude Carel, Shabir Madhi, Ben Marais, Frank Oberklaid, Susan Sawyer, Joan-Carles Surís
Journal: JAMA Pediatrics (2015)
JOSEPH BARCROFT, THE OXYGEN PHYSIOLOGIST
Authors: J. H. T.
Journal: JAMA (1961)

Joseph Barcroft, Professor of Physiology at Cambridge, lived, studied, and taught in the Golden Age of Physiology in England. He was born in The Glen near Newry, County Down, near the Belfast-Dublin Road in Northern Ireland, beyond the Mourne Mountains. He so loved his ancestral home that he returned to it regularly throughout his professional career. His parents were well-to-do Quakers, and made possible an excellent education. Franklin, in the biography of Barcroft,<sup>1</sup>described him as "precocious" because of the circumstances that surrounded his acceptance of the Bachelor of Science degree by London University at the age of 19. A dissertation entitled<i>An Investigation of the Gaseous Metabolism of the Salivary Glands</i>was one of the requirements for the Doctorate of Philosophy by Cambridge University. A glittering array of British and international physiologists were his associates, teachers, or pupils. These included J. N. Langley, M. Foster, W. H. Gaskell,
Smoking abstinence and small cell lung cancer survival. An association
Authors: A. Johnston-Early
Journal: JAMA (1980)

The prognostic implications of cigarette smoking were investigated in 112 patients with small cell lung cancer. Twenty had stopped smoking permanently before diagnosis (NS-Prior), 35 had stopped at diagnosis (NS-Dx), and 57 patients continued smoking (S). Therapies included chemotherapy alone or with radiation therapy, with or without thymosin fraction V. The survival difference among the three groups was statistically significant. The NS-Prior patients had the best survival, followed by NS-Dx patients and finally S patients. No S patient has survived, disease free, more than 96 weeks, while three NS-Prior and three NS-Dx patients are disease free 103 to 220 weeks after start of treatment. Thymosin, 60 mg/sq m, yielded survival benefits for the S group only. Continuation of smoking during the treatment of small cell lung cancer was associated with a poor prognosis, while discontinuation of smoking, even at diagnosis, may have beneficial effects on survival. (<i>JAMA</i>244:2175-2179, 1980)
Increased benzodiazepine-like activity is neither necessary nor sufficient to explain acute hepatic encephalopathy in the thioacetamide-treated rat
Authors: P Widler
Journal: Hepatology (1993)

Increased levels of natural benzodiazepine receptor agonists, produced in the body (endogenous) or ingested with food (exogenous) have been proposed as one of the factors causing hepatic encephalopathy in both experimental animals and human subjects. However, the divergent response of hepatic encephalopathy to benzodiazepine antagonists sheds doubt on this attractive hypothesis. Acute liver failure was induced in male Sprague-Dawley rats (n = 17) with intraperitoneal thioacetamide (600 mg/kg/day for 3 days) while 14 control rats received vehicle only. Acute liver failure developed in all treated rats (AST: 1,898 ± 1,359 IU/L vs. controls, 45 ± 5 IU/L, p < 0.005; bilirubin: 36 ± 27 μmol/L vs. controls, 1.5 ± 0.5 μmol/L, p < 0.005; centrizonal necrosis) and grade 3 or 4 hepatic encephalopathy (neurologic assessment and activity monitoring). However, benzodiazepine receptor ligand activity, measured in the supernatant of whole-brain homogenates with a [3H]fiumazenil binding competition assay, was clearly increased in only 1 of 17 rats with acute liver failure compared with controls (52.7 ± 34.1 vs. 44.3 ± 18.9 ng diazepam equivalents/gm; NS). To evaluate whether the reported increase in benzodiazepine receptor ligand activity could be due to prolonged residence of exogenous benzodiazepine-like substances, additional rats with acute liver failure and controls were treated with diazepam (five doses of 0.5 mg/kg at 12-hr intervals by gavage). Benzodiazepine receptor ligand activity was greater in animals with acute liver failure than in controls (223 ± 65 vs. 103 ± 23 ng diazepam equivalents/gm; p < 0.002) 1 to 3 hr after the last diazepam dose. Increased tissue levels of benzodiazepine receptor ligand activity are therefore neither necessary nor sufficient to explain the pathogenesis of hepatic encephalopathy in acute liver failure. We conclude that increased tissue levels of benzodiazepine receptor agonists in hepatic encephalopathy could be due to prolonged residence of exogenous benzodiazepine-like compounds of pharmaceutical or natural origin. (HEPATOLOGY 1993;18:1459–1464.)